Thromb Haemost 1990; 63(01): 013-015
DOI: 10.1055/s-0038-1645677
Original Article
Schattauer GmbH Stuttgart

Premature Arterial Disease Associated with Familial Antithrombin III Deficiency

E J Johnson
1   The Department of Haematology, Bradford Royal Infirmary, Bradford, West Yorkshire, UK
,
C R M Prentice
2   The Department of Medicine, Leeds General Infirmary, Leeds, West Yorkshire, UK
,
L A Parapia
1   The Department of Haematology, Bradford Royal Infirmary, Bradford, West Yorkshire, UK
› Author Affiliations
Further Information

Publication History

Received 18 July 1989

Accepted after revision 03 November 1989

Publication Date:
02 July 2018 (online)

Summary

Antithrombin III (ATIII) deficiency is one of the few known abnormalities of the coagulation system known to predispose to venous thromboembolism but its relation to arterial disease is not established. We describe two related patients with this disorder, both of whom suffered arterial thrombotic events, at an early age. Both patients had other potential risk factors, though these would normally be considered unlikely to lead to such catastrophic events at such an age. Thrombosis due to ATIII deficiency is potentially preventable, and this diagnosis should be sought more frequently in patients with arterial thromboembolism, particularly if occurring at a young age. In addition, in patients with known ATIII deficiency, other risk factors for arterial disease should be eliminated, if possible. In particular, these patients should be counselled against smoking.

 
  • References

  • 1 Yin ET, Wessler S, Stoll PJ. Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. J Biol Chem 1971; 246: 3712
  • 2 Biggs R, Benson KW E, Akman N, Barrett R, Hadden M. Antithrombin III, antifactor Xa and heparin. Br J Haematol 1970; 19: 283
  • 3 Winter JH, Fenech A, Ridley A, Bennett B, Cummings AM, Mackie M, Douglas AS. Familial antithrombin III deficiency. Quart J Med 1982; 204: 373-395
  • 4 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
  • 5 Woodhams BJ, Kernoff PB A. Rapid radioimmunoassay for fibrinopeptide A in human plasma. Thromb Res 1978; 22: 407-416
  • 6 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos Diathes Haemorrh 1965; 13: 516-530
  • 7 Winter J, Bennett B, Donald D, Douglas AS. Arterial thrombosis and accelerated atheroma in a member of a family with familial antithrombin III deficiency. Postgrad Med J 1982; 58: 108-109
  • 8 Hale CS, Mattson JC, Zuhlke JA. Familial antithrombin III deficiency associated with recurrent arterial thromboembolism. Thromb Haemostas 1981 46. (2) 285 (Abstr)
  • 9 Indeck M, Kerstein MD. Arterial thromboembolism and associated antithrombin III deficiency. South Med J 1983; 76: 1057-1058
  • 10 Bjorke B, Henin P, Blomback M. Neonatal Aortic Thrombosis, a possible clinical manifestation of cogenital antithrombin III deficiency. Acta Paediatr Scand 1974; 63: 297-301
  • 11 Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J 1976; 38: 659-664
  • 12 De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden M, Lang H. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
  • 13 Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; II: 899-993
  • 14 Lowe GD O, Drummond Maureen M, Lorimer AR, Hutton I, Forbes CD, Prentice CR M, Barbenel JC. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 673-677
  • 15 Meade TW, Chakrabarti R, Haines AP, North WR S, Stirling Y, Thompson SG. Haemostatic function and cardiovascular death; early results of a prospective study. Lancet 1980; 1050-1054